Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Agios Pharma (8AP) Stock Price & Analysis

8AP Stock Chart & Stats

€32.80-€1.20(-3.53%)
At close: 5:30 PM GMT+1
EUR 23.6EUR 23.8EUR 24EUR 24.223 Mar30 Apr
Day’s Range
EUR 32.80 - EUR 32.80
52-Week Range
EUR 19.70 - EUR 38.80
Previous Close
EUR 34.00
Volume
0
Average Volume (3M)
0
Market Cap
EUR 1.63B
Enterprise Value
EUR 1.62B
Total Cash (Recent Filing)
EUR 617.58M
Total Debt (Recent Filing)
EUR 31.17M
Price to Earnings (P/E)
―
Beta
1.20
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
-1.11
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Commercial Revenue Growth

Strong revenue growth and Q2 launch performance indicate that Agios is converting its approved-product opportunity into commercial sales. Continued adoption can broaden the revenue base, improve operating leverage over time, and support investment in additional hematology indications.

Strong Liquidity And Low Leverage

Agios has substantial liquidity relative to its low debt burden, providing financial flexibility to fund clinical development, commercial expansion, and regulatory activities. This balance-sheet capacity reduces near-term financing pressure while the company works toward improving profitability.

Pipeline Advancement

Multiple programs are advancing across hematology and metabolic disease, giving Agios opportunities to diversify beyond its current commercial product. Progress into later-stage development can expand the addressable portfolio and create additional future revenue opportunities.

Bears Say

Deep Losses And Cash Burn

Persistent losses and substantial negative cash flow show that current operations do not yet fund the company’s development and commercial activities. Continued spending at this level can consume liquidity and increase the importance of future product growth or external financing.

High Operating Expenses

Rising research and selling expenses are necessary to advance programs and support commercialization, but they currently widen the gap between revenue and operating costs. Unless investment produces sustained sales growth or pipeline value, operating leverage and earnings improvement may remain limited.

Delayed Sickle-cell Regulatory Catalyst

The extended review timeline postpones potential regulatory validation and the opportunity to commercialize mitapivat in sickle cell disease. This delays a possible expansion of the addressable market and prolongs dependence on existing products and pipeline execution.

Agios Pharma News

8AP FAQ

What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was €19.70 and its highest was €38.80 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is €1.63B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is in 4 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Jul 30, 2026. The company reported -€1.508 earnings per share for the quarter, missing the consensus estimate of -€1.477 by -€0.031.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.11.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 59,701,880 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -€1.508 in its last earnings report, missing expectations of -€1.477. Following the earnings report the stock price went down -2.564%.
Which hedge fund is a major shareholder of Agios Pharma?
Hedge funds hold Agios Pharma shares: the largest hedge-fund position in Agios Pharma is 2,039,328,186 shares, and hedge funds increased their holdings by 159.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology